Krystal Biotech (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the transaction, the insider directly owned 1,403,155 shares of the company’s stock, valued at approximately $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Krystal Biotech Trading Down 2.6%

Shares of KRYS opened at $253.69 on Friday. The stock has a 50 day moving average of $269.86 and a 200 day moving average of $218.28. The company has a market capitalization of $7.42 billion, a price-to-earnings ratio of 37.04 and a beta of 0.49. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on KRYS shares. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. The Goldman Sachs Group raised their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, February 18th. Jefferies Financial Group increased their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Zacks Research lowered shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus target price of $326.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth about $34,000. Sound Income Strategies LLC raised its stake in Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after acquiring an additional 127 shares during the period. UMB Bank n.a. lifted its holdings in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the period. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.